786-0 Renal cancer cell line-derived exosomes promote 786-0 cell migration and invasion in vitro

被引:36
作者
Chen, Gang [1 ]
Zhang, Yao [1 ]
Wu, Xiaohou [1 ]
机构
[1] Chongqing Med Univ, Dept Urol, Affiliated Hosp 1, Chongqing 400016, Peoples R China
基金
中国国家自然科学基金;
关键词
renal cancer; cancer cell derived-exosomes; invasion; migration; chemokine receptor type 4; MMP-9; RECEPTOR; BREAST; OVEREXPRESSION; PROLIFERATION; ANGIOGENESIS; PROGRESSION; EXPRESSION; CHEMOKINE;
D O I
10.3892/ol.2014.1962
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Emerging evidence indicates that cancer-derived exosomes contribute to angiogenesis, tumor immunology and invasion. However, whether cancer cell-derived exosomes regulate the migration and invasion of the cancer cell itself, and the underlying mechanisms are not well understood. In the present study, exosomes derived from the 786-0 human renal cancer cell line were isolated, purified and 100 mu g/ml were co-cultured with 786-0 cells for 24 h. The 786-0 cells were harvested for a cell invasion and migration assay. The expression of chemokine receptor type 4 (CXCR4) and matrix metalloproteinase-9 (MMP-9) in the 786-0 cells was examined by western blot analysis and revealed that the migration and invasion capabilities of the 786-0 cells were increased, however, the cell adhesion abilities were decreased as a result of the 24-h treatment with 786-0-derived exosomes. Furthermore, the expression levels of CXCR4 and MMP-9 in the 786-0 cells were increased. In conclusion, the 786-0 renal cancer cell line-derived exosomes increased migration and invasion, however, they decreased the adhesion ability of the 786-0 cells. The exosomes may have increased the CXCR4 and MMP-9 expression levels in the 786-0 cells. These findings indicated that renal tumor-derived exosomes may contribute to renal cancer development and progression.
引用
收藏
页码:1576 / 1580
页数:5
相关论文
共 28 条
[1]
[Anonymous], WORLD J UROL
[2]
Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences [J].
Balaj, Leonora ;
Lessard, Ryan ;
Dai, Lixin ;
Cho, Yoon-Jae ;
Pomeroy, Scott L. ;
Breakefield, Xandra O. ;
Skog, Johan .
NATURE COMMUNICATIONS, 2011, 2
[3]
Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials [J].
Coppin, Chris ;
Kollmannsberger, Christian ;
Le, Lyly ;
Porzsolt, Franz ;
Wilt, Timothy J. .
BJU INTERNATIONAL, 2011, 108 (10) :1556-1563
[4]
Total Flavonoids of Scutellaria barbata Inhibit Invasion of Hepatocarcinoma via MMP/TIMP in Vitro [J].
Dai, Zhi-Jun ;
Wang, Bao-Feng ;
Lu, Wang-Feng ;
Wang, Zhi-Dong ;
Ma, Xiao-Bin ;
Min, Wei-Li ;
Kang, Hua-Feng ;
Wang, Xi-Jing ;
Wu, Wen-Ying .
MOLECULES, 2013, 18 (01) :934-950
[5]
Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors [J].
Di Carlo, Angelina .
ONCOLOGY LETTERS, 2013, 5 (05) :1677-1681
[6]
Estimates of cancer incidence and mortality in Europe in 2008 [J].
Ferlay, J. ;
Parkin, D. M. ;
Steliarova-Foucher, E. .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (04) :765-781
[7]
Chemokine and Chemokine Receptor Expression in Kidney Tumors: Molecular Profiling of Histological Subtypes and Association With Metastasis [J].
Gahan, Jeffrey C. ;
Gosalbez, Miguel ;
Yates, Travis ;
Young, Ezekiel E. ;
Escudero, Diogo O. ;
Chi, Andrew ;
Garcia-Roig, Michael ;
Satyanarayana, Ramgopal ;
Soloway, Mark S. ;
Bird, Vincent G. ;
Lokeshwar, Vinata B. .
JOURNAL OF UROLOGY, 2012, 187 (03) :827-833
[8]
Jia W, 2013, EUR REV MED PHARMACO, V17, P1495
[9]
Exosomes in tumor microenvironment influence cancer progression and metastasis [J].
Kahlert, Christoph ;
Kalluri, Raghu .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2013, 91 (04) :431-437
[10]
Inflammation Induced by MMP-9 Enhances Tumor Regression of Experimental Breast Cancer [J].
Leifler, Karin Soderlund ;
Svensson, Susanne ;
Abrahamsson, Annelie ;
Bendrik, Christina ;
Robertson, Jennifer ;
Gauldie, Jack ;
Olsson, Anna-Karin ;
Dabrosin, Charlotta .
JOURNAL OF IMMUNOLOGY, 2013, 190 (08) :4420-4430